NDAINJECTIONINJECTABLE
Approved
Mar 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUADRAMET is a radiopharmaceutical injection containing samarium SM-153 lexidronam pentasodium, approved in 1997 for pain management in cancer patients with bone metastases. It is a radioactive agent that localizes to areas of increased bone turnover, delivering targeted radiation therapy to reduce bone pain.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting a smaller, defensive commercial team focused on retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
QUADRAMET offers limited career growth with zero linked job openings and minimal clinical development pipeline. This is a defensive, mature product best suited for professionals seeking stable, established market experience or transitional roles before company restructuring at LOE.
Brand ManagerAccount Executive
Worked on QUADRAMET at Remedy Plan Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.